Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.

@article{Goodman2017TumorMB,
  title={Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.},
  author={Aaron Goodman and Shumei M Kato and Lyudmila A. Bazhenova and Sandip Pravin Patel and Garrett M. Frampton and Vincent A. Miller and Philip J. Stephens and Gregory A. Daniels and Razelle Kurzrock},
  journal={Molecular cancer therapeutics},
  year={2017},
  volume={16 11},
  pages={
          2598-2608
        }
}
Immunotherapy induces durable responses in a subset of patients with cancer. High tumor mutational burden (TMB) may be a response biomarker for PD-1/PD-L1 blockade in tumors such as melanoma and non-small cell lung cancer (NSCLC). Our aim was to examine the relationship between TMB and outcome in diverse cancers treated with various immunotherapies. We reviewed data on 1,638 patients who had undergone comprehensive genomic profiling and had TMB assessment. Immunotherapy-treated patients (N… CONTINUE READING